JP2002534995A5 - - Google Patents

Download PDF

Info

Publication number
JP2002534995A5
JP2002534995A5 JP2000595705A JP2000595705A JP2002534995A5 JP 2002534995 A5 JP2002534995 A5 JP 2002534995A5 JP 2000595705 A JP2000595705 A JP 2000595705A JP 2000595705 A JP2000595705 A JP 2000595705A JP 2002534995 A5 JP2002534995 A5 JP 2002534995A5
Authority
JP
Japan
Prior art keywords
xaa
leu
pro
thr
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000595705A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002534995A (ja
Filing date
Publication date
Priority claimed from US09/234,208 external-priority patent/US7393823B1/en
Application filed filed Critical
Publication of JP2002534995A publication Critical patent/JP2002534995A/ja
Publication of JP2002534995A5 publication Critical patent/JP2002534995A5/ja
Pending legal-status Critical Current

Links

JP2000595705A 1999-01-20 2000-01-20 Ｈｅｒ−２結合アンタゴニスト Pending JP2002534995A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/234,208 US7393823B1 (en) 1999-01-20 1999-01-20 HER-2 binding antagonists
US09/234,208 1999-01-20
PCT/US2000/001484 WO2000044403A1 (en) 1999-01-20 2000-01-20 Her-2 binding antagonists

Publications (2)

Publication Number Publication Date
JP2002534995A JP2002534995A (ja) 2002-10-22
JP2002534995A5 true JP2002534995A5 (enExample) 2007-11-15

Family

ID=22880399

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000595705A Pending JP2002534995A (ja) 1999-01-20 2000-01-20 Ｈｅｒ−２結合アンタゴニスト

Country Status (6)

Country Link
US (4) US7393823B1 (enExample)
EP (1) EP1144004A4 (enExample)
JP (1) JP2002534995A (enExample)
AU (1) AU777422B2 (enExample)
CA (1) CA2361181C (enExample)
WO (1) WO2000044403A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541214B1 (en) 1998-11-13 2003-04-01 Oregon Heath Science University N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US7625859B1 (en) * 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7396810B1 (en) * 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
US6294349B1 (en) 1999-03-01 2001-09-25 University Of Mississippi Medical Ctr. Method of diagnosing and monitoring malignant breast carcinomas
CA2373721C (en) 1999-07-02 2013-10-15 Genentech, Inc. Compounds that bind her2
US6435873B1 (en) 2000-10-10 2002-08-20 3M Innovative Properties Company Medication delivery devices
WO2003014159A1 (en) * 2001-08-03 2003-02-20 Commonwealth Scientific And Industrial Research Organisation Methods of screening based on the egf receptor crystal structure
AU2003249728A1 (en) 2002-07-03 2004-01-23 The Curators Of The University Of Missouri ErbB-2 RECEPTOR TARGETING PEPTIDE
WO2004096139A2 (en) 2003-04-24 2004-11-11 Incyte Corporation Aza spiro alkane derivatives as inhibitors of metalloproteases
JP2007525187A (ja) * 2003-05-16 2007-09-06 レセプター・バイオロジクス・インコーポレイテッド イントロン融合タンパク質、ならびにその同定方法および使用方法
US20060286102A1 (en) * 2004-05-14 2006-12-21 Pei Jin Cell surface receptor isoforms and methods of identifying and using the same
AU2005294347A1 (en) * 2004-10-05 2006-04-20 Oregon Health And Science University Compositions and methods for treating disease
US20070087406A1 (en) * 2005-05-04 2007-04-19 Pei Jin Isoforms of receptor for advanced glycation end products (RAGE) and methods of identifying and using same
US20090170769A1 (en) * 2005-05-13 2009-07-02 Pei Jin Cell surface receptor isoforms and methods of identifying and using the same
WO2007058776A2 (en) * 2005-11-10 2007-05-24 Receptor Biologix, Inc. Hepatocyte growth factor intron fusion proteins
WO2007143600A2 (en) * 2006-06-05 2007-12-13 Incyte Corporation Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
CA2655205A1 (en) * 2006-06-12 2007-12-21 Receptor Biologix Inc. Pan-cell surface receptor- specific therapeutics
WO2008005983A2 (en) * 2006-07-06 2008-01-10 Molecular Logix, Inc. Pan-her antagonists and methods of use
MX2010003757A (es) * 2007-10-16 2010-04-27 Symphogen As Composiciones que comprenden multimeros optimizados de her1 y her3 y sus metodos de uso.
CA2761777A1 (en) * 2009-05-14 2010-11-18 Prometheus Laboratories Inc. Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
EP3043780A4 (en) * 2013-09-12 2017-04-26 Thomas Jefferson University Novel delivery compositions and methods of using same
WO2018071864A1 (en) 2016-10-13 2018-04-19 Thomas Jefferson University Delivery compositions, and methods of making and using same
WO2023168426A1 (en) 2022-03-03 2023-09-07 Enosi Therapeutics Corporation Compositions and cells containing mixtures of oligo-trap fusion proteins (ofps) and uses thereof
WO2024186690A2 (en) 2023-03-03 2024-09-12 Enosi Therapeutics Corporation Oligo-trap fusion proteins (ofps) and uses thereof

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
DE3485712D1 (de) 1983-03-11 1992-06-17 Sloan Kettering Inst Cancer Monoklonale antikoerper gegen menschliche nierenkrebsantigene und verfahren.
EP0491675A1 (en) 1984-01-30 1992-06-24 Imperial Cancer Research Technology Limited Improvements relating to growth factors
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US7838216B1 (en) 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5206152A (en) 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes
ATE130873T1 (de) 1988-04-18 1995-12-15 Applied Biotechnology Inc Nachweis der expression von neu genen und produkten.
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DK0474727T3 (da) 1989-05-19 1998-01-12 Genentech Inc HER2 ekstracellulært domæne
US5705157A (en) 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
AU645760B2 (en) 1989-08-04 1994-01-27 Berlex Laboratories, Inc. C-erbb-2 external domain: GP75
WO1991005264A1 (en) 1989-09-29 1991-04-18 Oncogenetics Partners Detection and quantification of neu related proteins in the biological fluids of humans
NZ237464A (en) 1990-03-21 1995-02-24 Depotech Corp Liposomes with at least two separate chambers encapsulating two separate biologically active substances
ATE153858T1 (de) 1990-04-06 1997-06-15 Univ Pennsylvania Ligand für das neu-gen-produkt
US5874528A (en) 1990-05-25 1999-02-23 Georgetown University Binding peptides which interact with ligand growth factors of the epidermal growth factor receptor and erbB-2 receptor
US5578482A (en) 1990-05-25 1996-11-26 Georgetown University Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses
US5149655A (en) 1990-06-21 1992-09-22 Agracetus, Inc. Apparatus for genetic transformation
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
ATE221915T1 (de) 1991-02-22 2002-08-15 American Cyanamid Co Identifizierung eines menschlichen rezeptor- tyrosinkinasegens
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
JP3955316B2 (ja) 1991-06-21 2007-08-08 ザ・ワルター・アンド・エリザ・ホール・インスティテュート・オヴ・メディカル・リサーチ 新規レセプター型チロシンキナーゼ及びその用途
WO1993003741A1 (en) 1991-08-22 1993-03-04 Becton, Dickinson & Company Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy
JPH07506242A (ja) 1992-01-09 1995-07-13 ヘルシンキ　ユニバーシティ　ホルディング　リミテッド Ｔｉｅ，新規内皮細胞受容体チロシンキナーゼ
US6331302B1 (en) 1992-01-22 2001-12-18 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US5861301A (en) 1992-02-20 1999-01-19 American Cayanamid Company Recombinant kinase insert domain containing receptor and gene encoding same
US5811098A (en) 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
JPH08508405A (ja) 1993-03-26 1996-09-10 トーマス ジェファーソン ユニバーシティ Ｉｇｆ−１レセプターアンチセンスオリゴヌクレオチドにより細胞の増殖を阻害し、且つ細胞を分化させる方法
US6340674B1 (en) 1993-03-26 2002-01-22 Thomas Jefferson University Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US6696548B2 (en) 1993-12-03 2004-02-24 St. Jude Children's Research Hospital Antibodies for recognition of alk protein tyrosine/kinase receptor
WO1995024190A2 (en) 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
AU2187595A (en) 1994-03-14 1995-10-03 New York University Medical Center Methods for treatment or diagnosis of diseases or conditions associated with abnormal signal transduction
US6045797A (en) 1994-03-14 2000-04-04 New York University Medical Center Treatment or diagnosis of diseases or conditions associated with a BLM domain
WO1995030331A1 (en) 1994-05-05 1995-11-16 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
US5770567A (en) 1994-11-14 1998-06-23 Genentech, Inc. Sensory and motor neuron derived factor (SMDF)
HRP950558A2 (en) 1994-11-15 1997-12-31 Scott M. Wilhelm Substituted 4-biarylbutric or biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors
US5783404A (en) 1995-04-13 1998-07-21 Amgen Inc. Methods and compositions for determining HER-2/neu expression using monoclonal antibodies
US5663144A (en) 1995-05-03 1997-09-02 The Trustees Of The University Of Pennsylvania Compounds that bind to p185 and methods of using the same
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
AU3251797A (en) 1996-07-05 1998-02-02 Mount Sinai Hospital Corporation Oligomerized receptors which affect pathways regulated by transmembrane ligands for elk-related receptor tyrosine kinases
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
ES2274549T3 (es) 1996-09-24 2007-05-16 MERCK & CO., INC. Compuestos para la inhibicion de la angiogenesis por terapia de genes .
US5910583A (en) 1996-11-04 1999-06-08 Duke University Antisense oligonucleotides against ERBB-2
US7125969B1 (en) 1996-11-27 2006-10-24 The Regents Of The University Of California ETS-related gene overexpressed in human breast and epithelial cancers
US20020137890A1 (en) 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
DE69838334T2 (de) 1997-06-18 2008-06-12 Merck & Co., Inc. (A New Jersey Corp.) Kdr, ein menschlicher tyrosin kinase rezeptor
JP4475803B2 (ja) 1997-10-15 2010-06-09 アボット・ラボラトリーズ Ｅ型肝炎ウイルスを検出するための方法および組成物
DE69920405T2 (de) 1998-02-04 2006-01-05 Genentech, Inc., South San Francisco Verwendung des heregulins als epithelzellenwachstumsfaktor
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
SI1308456T1 (sl) 1998-05-06 2008-02-29 Genentech Inc Ciscenje protiteles z ionsko izmenjevalno kromatografijo
US20030036114A1 (en) 1998-05-15 2003-02-20 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU4278299A (en) 1998-06-11 1999-12-30 Astrazeneca Ab Human receptor tyrosine kinase
US7173005B2 (en) 1998-09-02 2007-02-06 Antyra Inc. Insulin and IGF-1 receptor agonists and antagonists
WO2000027426A1 (en) 1998-11-07 2000-05-18 Genentech, Inc. Method for enhancing proliferation of inner ear hair cells using ligands for her2 and/or her3 receptors
US6541214B1 (en) 1998-11-13 2003-04-01 Oregon Heath Science University N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
WO2000035455A1 (en) 1998-12-15 2000-06-22 Telik, Inc. Heteroaryl-aryl ureas as igf-1 receptor antagonists
US7396810B1 (en) 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US6399743B1 (en) 1999-05-14 2002-06-04 Dept. Of Veterans Affairs Isolation and characterization of a rat epidermal growth factor related protein
CA2373721C (en) 1999-07-02 2013-10-15 Genentech, Inc. Compounds that bind her2
CA2384264A1 (en) 1999-10-15 2001-04-26 Human Genome Sciences, Inc. Protein tyrosine kinase receptor polynucleotides, polypeptides, and antibodies
IL152656A0 (en) 2000-05-19 2003-06-24 Genentech Inc Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
TWI317285B (en) 2000-07-28 2009-11-21 Dainippon Sumitomo Pharma Co New use and kit for remedies for cancer
WO2002011677A2 (en) 2000-08-09 2002-02-14 Imclone Systems Incorporated Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
EP1228766A1 (en) 2001-01-31 2002-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PYK2 phosphorylation by HER3 induces tumor invasion
US6780912B2 (en) 2001-02-26 2004-08-24 Hewlett-Packard Development Company L.P. Addition of metal ions to improve lightfastness of inkjet inks
EP1395828A2 (en) 2001-05-03 2004-03-10 Oxford GlycoSciences (UK) Limited Proteins and genes for diagnosis and treatment of erbb2-related cancer
EP1390472A4 (en) 2001-05-29 2004-11-17 Sirna Therapeutics Inc NUCLEIC ACID TREATMENT OF DISEASES OR SIDES RELATED TO RAS, HER2 AND HIV LEVELS
US7125680B2 (en) 2001-07-27 2006-10-24 The Regents Of The University Of California Methods and materials for characterizing and modulating interaction between heregulin and HER3
WO2003025141A2 (en) 2001-09-19 2003-03-27 Intergenetics Incorporated Genetic analysis for stratification of cancer risk
US20050123896A1 (en) 2001-10-25 2005-06-09 Benz Christopher C. Screening system for modulators of her2 mediated transcription and her2 modulators identified thereby
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
AU2003210549A1 (en) 2002-01-18 2003-09-02 Chiron Corporation Combination il-2/anti-herz antibody therapy for cancers characterized by overexpression of the her2 receptor protein
ES2401428T3 (es) 2002-04-10 2013-04-19 Genentech, Inc. Variantes de anticuerpos anti-HER2
EP2263691B1 (en) 2002-07-15 2012-08-29 F.Hoffmann-La Roche Ag Treatment of cancer with the recombinant humanized monoclonal anti-erbb2 antibody 2C4 (rhuMAb 2C4)
TW200420565A (en) 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
JP2007525187A (ja) 2003-05-16 2007-09-06 レセプター・バイオロジクス・インコーポレイテッド イントロン融合タンパク質、ならびにその同定方法および使用方法
CN100392074C (zh) 2003-10-15 2008-06-04 上海海欣生物技术有限公司 树突状细胞肿瘤疫苗及其制法和用途

Similar Documents

Publication Publication Date Title
JP2002534995A5 (enExample)
VAN BERKEL et al. N-terminal stretch Arg2, Arg3, Arg4 and Arg5 of human lactoferrin is essential for binding to heparin, bacterial lipopolysaccharide, human lysozyme and DNA
CA2399387C (en) Heterologous polypeptide of the tnf family
CA2361181A1 (en) Her-2 binding antagonists
EP1534320B1 (en) Apolipoprotein l-i for the treatment of trypanosomal diseases
US10695404B2 (en) Treatment of steroid-induced hyperglycemia with fibroblast growth factor (FGF) 1 analogs
AU2001234953A1 (en) Heterologous polypeptide of the TNF family
JP2010000082A (ja) Ｉｇｆ−１レセプターと相互作用するタンパク質、それをコードする遺伝子及びそれらの使用
JP2004501605A5 (enExample)
CA2319715A1 (en) Breast cancer resistance protein (bcrp) and the dna which encodes it
EP1796711A2 (en) Herstatin or intron 8-encoded domain thereof for modulating signaling mediated by igf-1 receptor and erbb receptors
JP2006325596A (ja) シアロアドヘシンファミリーメンバー−２（ｓａｆ−２）
IL139852A (en) Monoclonal antibodies directed against the G3BP protein, and uses
US8735355B2 (en) Methods of use of fragments of secreted frizzled related protein, sFRP
US6114515A (en) PIGRL-1, a member of immunoglobulin gene superfamily
WO2001009368A1 (en) Follistatin antagonists
JP2002527037A (ja) サイトカインファミリーメンバーｅｆ−７
TOBE et al. Amino Acid Sequences of 60B8 Antigens Induced in HL-60 Cells by 1, 25-Dihydroxyvitamin D3: The Antigens Are Identical with Macrophage-Related Protein-14 and-8
JP2003512291A (ja) ガレクチン１１
JP2002513548A (ja) サイトカインファミリーメンバー２−１９
LT4877B (lt) Prv-1 genas ir jo panaudojimas
JP3694731B2 (ja) ミッドカインの受容体およびミッドカイン依存性の細胞生存を抑制する方法
WO2001064879A2 (en) G-proteins coupled receptor related polypeptides
JP2002281987A (ja) Ｓｂｐｅｒｒ４ポリペプチドおよびポリヌクレオチド
Autierol et al. Italy zyxwvutsrqponmlkjihgfe